BioCentury
ARTICLE | Company News

Canbridge, WuXi team up to develop rare disease therapies in China

October 23, 2018 7:20 PM UTC

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China in 2019.

The partnership will combine WuXi's early drug discovery and manufacturing capabilities with the Canbridge team’s experience in rare diseases. WuXi is eligible for undisclosed upfront payments, milestones and royalties. Canbridge has an exclusive license to develop the therapeutics worldwide...